GlaxoSmithKline PLC (LON:GSK) will submit US and European applications this year for a new smoker’s cough treatment after encouraging final trial results.
Glaxo, which is developing the treatment in partnership with us firm Innoviva INc. (NASDAQ:INVA), said the Phase III study showed its new triple combination therapy inhaler, FF/UMEC/VI outscored the current standard treatment, Symbicort Turbohaler.
Lung function and life quality also improved in patients with severe chronic obstructive pulmonary disease (COPD).
Dave Allen, Glaxo’s head of respiratory R&D, said he was delighted with the outcome of the FULFIL study.
“Triple combination therapy is already a reality for many patients with COPD and is dispensed in multiple inhalers.
“By combining three medicines in a single inhaler we can offer a convenient, once-daily dosing option to patients while improving their symptoms."
Mike Aguiar, Innoviva’s chief executive, added that if approved, a once-daily triple combination "would be an important addition to our portfolio of combination respiratory products partnered with GSK including Relvar/Breo Ellipta and Anoro Ellipta."